Importance
==========

Ebola virus (EBOV) causes severe human disease. The natural host reservoir of EBOV remains unknown. EBOV is distantly related to Marburg virus (MARV), which has been found in wild bats. The glycoprotein of a reptarenavirus known to infect snakes (boas and pythons) is similar in sequence and structure to those of EBOV and MARV. We demonstrate that JK, a boa constrictor cell line, and DpHt, a diamond python heart cell line, do not support MARV infection, but do support EBOV infection without cytotoxicity. These findings suggest that ebolaviruses and marburgviruses may not share identical ecological niches and that filovirus host search efforts may have to be broadened.

1. Introduction
===============

Ebola virus (EBOV) is one of five classified members of the genus *Ebolavirus* in the mononegaviral family *Filoviridae*. Four classified ebolaviruses (Bundibugyo virus, EBOV, Sudan virus, and Taï Forest virus) are known to cause Ebola virus disease (EVD), whereas the fifth classified member, Reston virus (RESTV), is thought to be nonpathogenic for humans. EVD is clinically indistinguishable from Marburg virus disease (MVD), which is caused by the two members of the filoviral genus *Marburgvirus* (Marburg virus \[MARV\] and Ravn virus \[RAVV\]) ([@vey034-B30]). The largest recorded EVD outbreak, caused by EBOV, began in Western Africa in December 2013 and ended in March 2016, infecting 28,646 and killing 11,323 people ([@vey034-B63]). Like the vast majority of EVD outbreaks ([@vey034-B29]; [@vey034-B63]), this outbreak started with a single introduction of EBOV from an unknown wild host reservoir host into a human, with subsequent human-to-human transmission ([@vey034-B2]; [@vey034-B12]; [@vey034-B7]; [@vey034-B31]; [@vey034-B39]; [@vey034-B48]; [@vey034-B54]).

Frugivorous bats are often discussed as potential ebolaviral host reservoirs, but supporting data are overall sparse. These data stem largely from detection of anti-EBOV or anti-RESTV antibodies, short, EBOV genome-like RNA fragments by reverse transcriptase-polymerase chain reaction (RT-PCR), or filovirus-like endogenous viral elements. Ebolaviruses pathogenic for humans have not yet been recovered from any wild bat; complete genomes of pathogenic ebolaviruses have not yet been sequenced from wild bats; and experimental infections of frugivorous bats with ebolaviruses pathogenic for humans have thus far failed ([@vey034-B57]; [@vey034-B22]; [@vey034-B33]; [@vey034-B40]). However, a novel ebolavirus not known to cause disease in any animal, Bombali virus (BOMV), has recently been discovered by next-generation sequencing in oral and anal swabs of Angolan free-tailed bats (*Mops condylurus*) and little free-tailed bats (*Chaerephon pumilus*). This finding indicates that at least some ebolaviruses may infect bats ([@vey034-B13]). In contrast, genetically diverse MARV and RAVV, both of which cause human disease, were repeatedly isolated from wild Ugandan Egyptian rousettes (*Rousettus aegyptiacus*) in direct vicinity of human infections ([@vey034-B55]; [@vey034-B1]), and experimental infections of Egyptian rousettes were successful in the laboratory ([@vey034-B22]).

Together, these findings suggest that ebolaviruses and marburgviruses may differ in host tropism. However, few filovirus genus-specific cell susceptibility/permissiveness differences have been uncovered *in vitro*. Notably, African straw-colored fruit bat (*Eidolon helvum*) cells are refractory to EBOV, based on a single amino acid change in the filovirus receptor and binding partner of the EBOV glycoprotein GP~1~,~2~, Niemann-Pick disease, type C1 protein (NPC1) ([@vey034-B38]). No cell line known to the authors has the opposite differential permissiveness to MARV and EBOV, that is, cell lines permissiveness to ebolavirus infection typically also support marburgvirus infection independent of species origin ([@vey034-B29]). Additionally, until now, filoviruses, and specifically EBOV, have only been shown to infect mammalian-derived cell lines.

The recent discovery of a possible evolutionary relationship between the glycoprotein (*GP*) genes of filoviruses and snake-infecting reptarenaviruses (*Arenaviridae*: *Reptarenavirus*) ([@vey034-B11]; [@vey034-B1]; [@vey034-B50]) prompted us to test the filovirus permissiveness of two snake cell lines. We demonstrate that both boa constrictor JK cells ([@vey034-B50]) and diamond python DpHt cells support EBOV replication; that EBOV infection of both cell lines is not accompanied by cytopathic effect (CPE); that JK cells can be infected over multiple passages with EBOV, but not with MARV; and that EBOV does not undergo major genomic adaptation while replicating in JK cells. We also show that MARV restriction occurs at a post-entry stage, most likely during early transcription/replication. Our data support the hypothesis that fundamental differences exist in ebolavirus and marburgvirus host tropism in the wild and indicate a need for further investigation of filovirus host tropism using non-mammalian cell lines.

2. Materials and methods
========================

2.1 Filovirus stock preparation
-------------------------------

Infections with Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 (reference genome GenBank [\#KT582109](#KT582109); EBOV) ([@vey034-B26]) and Marburg virus/H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke (reference genome GenBank [\#DQ217792](#DQ217792); MARV) ([@vey034-B49]) were conducted under biosafety level 4 conditions at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). EBOV and MARV were propagated in grivet (*Chlorocebus aethiops*) kidney epithelial Vero E6 cells (American Type Culture Collection, Manassas, VA, \#CCL-1586) and titrated by plaque assay as described previously ([@vey034-B36]; [@vey034-B47]; [@vey034-B46]).

2.2 Vesiculovirus virus infection assay
---------------------------------------

Recombinant vesicular stomatitis Indiana viruses (rVSVs) genetically encoding enhanced green fluorescent protein (eGFP) and EBOV or MARV GP~1~,~2~ protein (rVSV-EBOV GP~1~,~2~ and rVSV-MARV GP~1~,~2~, respectively) were previously rescued from cDNAs ([@vey034-B35]; [@vey034-B61]). These viruses were titered on Vero cells (American Type Culture Collection, \#CCL-81) as described previously ([@vey034-B61]). Vero cells and boa constrictor (Squamata: Boidae: *Boa constrictor*) kidney JK cells described previously ([@vey034-B50]) were plated in respective wells. The next day, cells were infected, and the infection rate was calculated by counting eGFP-positive cells 14--16 h later.

2.3 Filovirus immunostaining
----------------------------

JK, diamond python (Squamata: Pythonidae: *Morelia spilota*) heart (DpHt), or human epithelial adenocarcinoma HeLa cells infected with EBOV or MARV were stained with murine monoclonal antibodies against EBOV or MARV GP~1~,~2~ (6D8 and 9G4 antibody, respectively), followed by Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, Thermo Fisher Scientific Waltham, MA, USA) for high-content quantitative image-based analysis. Infected cells were also stained with Hoechst 33342 (blue) and HCS CellMask Red (Invitrogen, Thermo Fisher Scientific) for nuclei and cytoplasm detection, respectively. Infection rates and cell numbers were determined using high-content quantitative imaging data on an Opera quadruple excitation high sensitivity confocal reader (model 3842 and 5025; PerkinElmer, Waltham, MA, USA) at two exposures using ×10 air, ×20 water, or ×40 water objective lenses as described in ([@vey034-B42]). Analysis of the images was accomplished within the Opera environment using standard Acapella scripts.

2.4 Filovirus virus serial passage
----------------------------------

EBOV or MARV were passaged in either JK cells or HeLa cells (American Type Culture Collection \#CCL2). For each of the serial passages, JK cells and HeLa cells were plated in six-well plates (at 300,000 cells/well, three replicates per cell line per virus). One day later, cells were exposed to EBOV or MARV at a multiplicity of infection (MOI) of 1. Briefly, exposure was performed by first removing media from cells, incubating cells with media containing filovirus for 1 h, washing cells, and finally adding fresh media back to cells. Infected cells were then incubated at 37°C in a 5 per cent CO~2~ atmosphere for 4 or 5 days ([Fig. 1](#vey034-F1){ref-type="fig"}). Supernatants were collected at the indicated time points; 50 µl were used to infect monolayers of fresh cells; and 1.5 ml were added to Trizol (Thermo Fischer Scientific) for sequencing.

![Schematic of the viral passaging experimental procedure. Plated cells, either boa constrictor JK or human HeLa cells, were infected with EBOV for 1 h and then grown for either 4 or 5 days. To passage virus, supernatants were removed and a 1/40 subsample (50 µl) was used to inoculate a fresh monolayer of cells. In addition, 1.5 ml of the supernatant was inactivated for sequencing. This procedure was repeated for a total of six passages of EBOV.](vey034f1){#vey034-F1}

2.5 Quantification of filoviral titers by qRT-PCR
-------------------------------------------------

JK cells were infected with EBOV or MARV (MOI = 1) or mock infected (no virus). At the experimental endpoint, media were harvested for qRT-PCR and/or cells were fixed with formalin (Val Tech Diagnostics, Pittsburgh, PA, USA) prior to immunostaining. For qRT-PCR, RNA was extracted with Trizol (Thermo Fischer Scientific) and the Ambion Blood RNA Isolation Kit (Thermo Fischer Scientific). The assay was performed with RNA UltraSense one-step kit (Thermo Fisher Scientific) and TaqMan probe (ABI, Thermo Fischer Scientific) following the manufacturer's instructions. The primers used were: EBOGP_For (TGGGCTGAAAACTGCTACAATC), EBOGP_Rev (CTTTGTGCACATACCGGCAC), probe EBOGP_Prb (5-6FAM-CTACCAGCAGCGCCAGACGG-TAMRA) ([@vey034-B42]), and MARV_GP2_F (TCACTGAAGGGAACATAGCAGCTAT), MARV_GP2_R (TTGCCGCGAGAAAATCATTT), and probe MARV_GP2_P (ATTGTCAATAAGACAGTGCAC). Serial 10-fold dilutions (10^2^ to 10^7^) of the assayed virus genomes (RNA) were used as standards.

2.6 Passage population size measurement
---------------------------------------

The number of EBOV genomes that each cell passage produced and the number of genomes added to sequencing libraries were determined by two-step reverse transcription droplet digital PCR (RT-ddPCR) ([@vey034-B18]). EBOV RNA was reverse-transcribed using EBOV-specific primer EBOGP_For (TGGGCTGAAAACTGCTACAATC), diluted, and assayed with the Bio-Rad Qx200 Droplet Digital PCR System (Bio-Rad, Hercules, CA USA) following the manufacturer's instructions.

2.7 Sequencing-library preparations
-----------------------------------

Trizol-inactivated samples were prepared for Illumina sequencing using a protocol slightly modified from our previously published protocol ([@vey034-B51]). Briefly, complementary DNA (cDNA) was created from randomly primed RNA using SuperScript VILO Master Mix (Thermo Fisher Scientific). cDNA was tagmented using Illumina's Nextera reagents (Illumina, San Diego, CA, USA), followed by dual-barcoding to prevent miscalling of samples ([@vey034-B60]). Libraries were quantified by qPCR, pooled, size-selected using BluePippin (Sage Science, Beverly, MA, USA), amplified, quantified again by qPCR, and paired-end sequenced (150/150 bases) on an Illumina HiSeq 4000 system at the University of California, San Francisco Center for Advanced Technology. Samples HeLa-P1-R1 (Host-Passage-Replicate) and JK-P1-R1 through JK-P6-R1 were prepared and sequenced separately using the same method and sequencer.

2.8 Single nucleotide variant analysis pipeline
-----------------------------------------------

Sequencing reads were filtered to remove reads containing sequencing adapters or having a quality below the cut-off of at least 95 per cent of the sequence having a 0.98 probability being correct (-rqf 95 0.98) with PriceSeqFilter from PRICE (version 1.2) ([@vey034-B43]). Filtered reads were aligned to the EBOV reference genome \[GenBank [\#KT582109](#KT582109) bases 1--18,882\] using GSNAP (version 2015-09-29) ([@vey034-B64]) with default settings.

Because of the very high coverage in each sample, duplicate reads were not removed, a step usually taken in single nucleotide variant (SNV) analysis. Sorted and indexed BAM files were processed with LoFreq\* (version 2.1.2) ([@vey034-B59]), using default settings, to call SNVs. A final cut-off of ≥0.005 allele frequency was selected as a conservative threshold, calculated as 1.25 SDs above the mean of each nucleotide's maximum detected allele frequency (0.00339, σ = 0.00129) of the Illumina supplied PhiX control sequence, which was included in each sequencing run. SNVs were then determined to be either synonymous or non-synonymous. Analysis was performed and graphs were generated using Python3, IPython ([@vey034-B41]), pandas ([@vey034-B34]), matplotlib ([@vey034-B19]), and seaborn ([@vey034-B58]).

2.9 Testing for selection
-------------------------

Briefly, we developed a simulation-based procedure to identify alleles in the EBOV genome that changed frequency over passages more than expected under neutrality given the dynamic viral population size and estimated sequencing error rates (see [Supplementary Methods](#sup3){ref-type="supplementary-material"}). The neutral simulations had five parameters: the overall population growth function, the number of generations, the starting allele frequency, and the read depth for each site during the first and last passage.

2.10 Detection of defective interfering genomes
-----------------------------------------------

Sequencing reads were processed in the same way as for SNV analysis. For each passage point, only properly paired reads were used. All of the passages in JK cells replicate 1 (JK-R1) and the passage HeLa cells replicate 1 passage 1 (HeLa-R1-P1) had a sizable drop in Q-score during sequencing of read 2. These reads were filtered out during pre-processing, necessitating that these paired-end reads be mapped as a combined single-end sample for each of the above passages. These combined samples then lacked proper pairing and were not used in defective interfering (DI) genome analysis. Each of the properly paired reads was also confirmed for the correct mapping orientation. Then the 'reference location' located in each sample's BAM file was used as that read's mapping location, and the distance difference between the read 1 mapping location and read 2 mapping location was calculated along with the mean and SD for the entire set. Proper pairs characterized by a distance difference greater than the mean + 3σ were counted as reads coming from potential DI genomes.

2.11 Measurement of cytopathic effects
--------------------------------------

Cell numbers were measured as an indication of CPE (see 'Section 2.3 Filovirus immunostaining' for experimental details). Briefly, infected cells were also stained with Hoechst 33342 and HCS CellMask Red for nuclei and cytoplasm detection, respectively. Cell numbers were determined using high-content quantitative imaging data on an Opera quadruple excitation high sensitivity confocal reader.

2.12 Boa constrictor NPC1 sequencing
------------------------------------

The boa constrictor NPC1 mRNA sequence was predicted using a draft boa constrictor genome assembly (assembly 'snake_1C') generated as part of the Assemblathon 2 competition ([@vey034-B4]). The NPC1 genomic locus is contained on scaffold SNAKE00002789 of the assembly. NPC1 exons were predicted by: (1) comparing to the predicted Burmese python (Squamata: Pythonidae: *Python bivittatus*) NPC1 mRNA (XM_015889305.1); (2) mapping boa constrictor RNA-Seq reads contained in SRA datasets SRR941243 and SRR941236 to the genomic scaffold and to the predicted mRNA/cDNA sequence to validate the predicted exons; (3) comparing the predicted NPC1 protein to other NPC1 protein sequences; and (4) PCR and Sanger sequencing across the predicted sequence, with PCR protocols as described previously ([@vey034-B50]). PCR primers used for PCR and Sanger sequencing are listed in [Supplementary Table S3](#sup6){ref-type="supplementary-material"}.

3. Results
==========

3.1 EBOV and Marburg virus glycoproteins facilitate vesiculovirus infection into snake cells
--------------------------------------------------------------------------------------------

To test whether snake cells can internalize filoviruses, we first quantified the infection rate of rVSV-EBOV and rVSV-MARV into boa constrictor JK cells and compared it to the infection rate into grivet Vero cells. We used pairwise Welch's *t*-tests to examine if the infection rates were significantly different between the cell lines or between the viruses. For both cell lines, rVSV-MARV generally had a higher rate of infection ([Fig. 2](#vey034-F2){ref-type="fig"}). In Vero cells, the difference in infection was significant; the rVSV-MARV titer was 1.035 × 10^7^ infection units (IU) (standard error of the mean \[SEM\] 2.12 × 10^6^ IU) versus rVSV-EBOV titer of 3.05 × 10^6^ IU (SEM 5.65 × 10^5^ IU) (*P *=* *0.0171). In JK cells, the difference was also significant; rVSV-MARV titer was 1.47 × 10^5^ IU (SEM 1.67 × 10^4^ IU) versus the rVSV-EBOV titer of 4.27 × 10^4^ IU (SEM 5.16 × 10^3^ IU) (*P *=* *0.00106). In inter-host-type comparisons, JK cells versus Vero cells, JK cells generally had a lower rate of infection; rVSV-MARV infected JK cells at a very significant infection rate, 1.47 × 10^5^ IU (SEM 1.67 × 10^4^ IU) versus 1.04 × 10^7^ IU (SEM 2.12 × 10^6^) in Vero cells (*P *=* *0.0048). rVSV-EBOV infected both cell types at similar rates, 4.27 × 10^4^ IU (SEM 5.16 × 10^3^ IU) in JK cells versus 3.05 × 10^6^ IU (SEM 5.65 × 10^5^ IU) in Vero cells (*P *=* *0.0031). Together, these data indicate that both EBOV and MARV glycoproteins bind to and facilitate recombinant vesiculovirus entry into snake cells.

![Infection rate of filovirus GP~1,2~-expressing rVSV particles (rVSV-EBOV, rVSV-MARV) on JK cells versus Vero cells. Error bars are equal to the SEM.](vey034f2){#vey034-F2}

3.2 EBOV, but not Marburg virus, replicates efficiently in snake cells
----------------------------------------------------------------------

As the vesiculovirus infection assay indicated that snake JK cells support GP~1,2~-mediated internalization of both rVSV-EBOV and rVSV-MARV, we next tested whether filoviruses can replicate in these cells. We exposed JK cells and diamond python DpHt cells to either EBOV or MARV at MOIs of 1, 5, 10, or no virus (mock). At 72 h after exposure, cells were fixed and stained for filoviral antigen (GP~1,2~) detection ([@vey034-B42]). Based on immunostaining, both cell lines supported infection of EBOV with dose-dependent infection rates ([Fig. 3A](#vey034-F3){ref-type="fig"}). As expected, mock-exposed cells showed little signs of infection; 0.02 per cent (σ  =  0.03) of JK cells were antigen-positive and 0.06 per cent (σ  =  0.07) of DpHt cells were antigen-positive. As the MOI increased to 1, 5, or 10 in JK cells, the number of positive cells increased to 80.64 per cent (σ  =  3.74) (two of the nine wells were not counted for this MOI as they had too few cells), 97.88 per cent (σ  =  1.00), or 99.06 per cent (σ  =  0.29), respectively. Similarly, with the same incremental increases in MOIs, the number of positive DpHt cells increased to 4.10 per cent (σ  =  1.75), 25.28 per cent (σ  =  6.36), or 42.49 per cent (σ  =  4.62), respectively.

![Immunostaining-based filovirus infection rates of snake cell lines. JK cells or DpHt cells were inoculated with EBOV or MARV at MOI of 0 (mock), 1, 5, or 10. At 72 h post-inoculation, supernatant was removed, and cells were fixed. Cells were then stained with Hoechst 33342, HCS CellMask Red, primary antibodies against EBOV or MARV GP~1~,~2~, and secondary antibodies. The box represents the quartiles and its whiskers extend 150 per cent of the interquartile length. JK cell counts are green, and DpHt cells are dark yellow. EBOV-infected cell counts are depicted in bold; MARV-infected cell counts are in pastel. (A) Percent of cells counted that stained positive for anti-GP~1~,~2~. (B) Total number of cells counted per well of plated snake cell lines.](vey034f3){#vey034-F3}

Surprisingly, infection rates of cells inoculated with MARV resembled those of mock exposure in both snake cell lines. Based on immunostaining, we measured MARV infection for the mock treatment at 0.24 per cent (σ  =  0.18) for JK cells and 0.02 per cent (σ  =  0.02) for DpHt cells. In JK cells, the number of positive cells increased to 0.24 per cent (σ  =  0.07), 0.82 per cent (σ  =  0.59), or 1.65 per cent (σ  =  0.29) as the MOI increased to 1, 5, or 10, respectively. In DpHt cells, the number of positive cells increased to 0.02 per cent (σ  =  0.05), 0.45 per cent (σ  =  0.35), or 1.84 per cent (σ  =  0.82) as the MOI increased to 1, 5, and 10, respectively. HeLa cells infected with MARV and stained with the same antibody were used as a positive control for the assay and demonstrated its validity (data not shown). Together, these data indicate that snake cells from snakes of at least two diverse species are permissive to EBOV infection but resistant to MARV infection. To our knowledge, JK and DpHt cells represent the first reptilian cell lines permissive to filovirus infection.

3.3 EBOV replicates efficiently in boa constrictor cells over multiple passages
-------------------------------------------------------------------------------

To characterize whether any adaptive genomic mutations are necessary for efficient growth in snake cells, we serially passaged EBOV in JK cells in parallel with control human (HeLa) cells for six cycles (an average of 4.33 days per cycle) ([Fig. 1](#vey034-F1){ref-type="fig"}) and MARV, analogously, for five cycles. HeLa cells were chosen as the control because they have been routinely used in filovirus research for both EBOV and MARV ([@vey034-B29]). Furthermore, as the viral stocks had been propagated in Vero cells, we could not use Vero cells for virus adaptation studies. The infection of both JK and HeLa cells was initiated at an MOI of 1.

For each passage cycle of EBOV, the extent of infection was monitored by qRT-PCR, immunostaining, and RT-ddPCR. EBOV was detected by qRT-PCR in media from both JK and HeLa cells at all passages. At all passages, EBOV-infected JK cells were characterized by clusters of EBOV GP~1,2~-positive cells, with predominantly cytoplasmic and cell membrane staining that was similar to staining in EBOV-infected HeLa cells ([Fig. 4](#vey034-F4){ref-type="fig"}). Over the course of these passages, the number of EBOV genome equivalents produced by infected JK cells was modestly lower than that observed with infected HeLa cells. Quantification of EBOV genome copy numbers in the supernatants from passages in JK cells by RT-ddPCR yielded an average of 8.49 × 10^8^ copies/ml (σ  =  9.92 × 10^8^ copies/ml) across all passages and replicates, whereas HeLa cells yielded an average genome copy number of 6.34 × 10^9^ copies/ml (σ  =  5.88 × 10^9^ copies/ml). The EBOV genome copy number measured in the JK supernatants was not significantly different between the first and last passage (4.34 × 10^9^ versus 1.79 × 10^9^ copies/ml, *P *=* *0.4, Welch's *t*-test).

![Antibody staining of EBOV GP~1,2~. Cells infected with EBOV were stained with HCS CellMask Red for cytoplasm (shown in red) and for anti-GP~1,2~ antibody (shown in green).](vey034f4){#vey034-F4}

For each passage cycle of MARV (projected negative control), the extent of infection was monitored by qRT-PCR. As expected, MARV was detected in the media of all passages in HeLa cells, but only in the media following the first passage in JK cells ([Supplementary Table S2](#sup5){ref-type="supplementary-material"}).

We used a deep sequencing approach to characterize the spectrum of possible mutations associated with EBOV adaptation to JK cells. For each passage, total cell culture supernatant RNA was processed into cDNA libraries for deep sequencing by random priming. For each library, sequencing reads were aligned to the EBOV reference genome. The mean coverage of the EBOV genome in JK cells across all passages was 36,730-fold (σ  =  12,016) and 69,946-fold (σ  =  26,582) for HeLa cell passages ([Fig. 5](#vey034-F5){ref-type="fig"}). We detected no regional bias of coverage at any point within the genome in any of the three biological replicates of infected JK and HeLa cells, excluding the extreme 5′ and 3′ ends. Previous characterization of cells infected with either EBOV or MARV using deep sequencing yielded a pronounced gradient of filovirus gene transcription similar to that seen for other mononegaviruses. Transcripts accumulate in the 3′ to 5′ direction, with the furthest 3′ gene (encoding the filoviral nucleoprotein \[NP\]) yielding the highest coverage and the furthest 5′ gene (encoding the filoviral RNA-dependent RNA polymerase \[L\]) yielding the lowest coverage ([@vey034-B45]). For the data presented here, the lack of a 3′ to 5′ coverage gradient is consistent with sequence reads derived from EBOV genomic RNA in cell culture supernatant virions, as opposed to cellular EBOV transcripts ([Fig. 5](#vey034-F5){ref-type="fig"}).

![Mean coverage maps of deep sequencing reads mapped to the EBOV reference genome. The EBOV reference genome schematic was drawn to scale between both maps. The number of reads that map to each genome base position was computed for each sample. For each replicate passage series for either HeLa (top graph: EBOV inoculum, red; HeLa-R1, blue; HeLa-R2, green; HeLa-R3, purple) or JK cells (bottom graph: EBOV inoculum, red; JK-R1, blue; JK-R2, green; JK-R3, purple), the mean coverage (respectively colored solid lines) was calculated and graphed.](vey034f5){#vey034-F5}

In summary, these data identify boa constrictor JK cells as permissive to EBOV, but not to MARV infection. To our knowledge, JK cells represent the first cell line with filovirus genus-specific (ebolavirus versus marburgvirus) permissiveness to EBOV infection.

3.4 EBOV adaption is not required for efficient infection of boa constrictor cells
----------------------------------------------------------------------------------

We first characterized the extent of variation within the EBOV inoculum population. We detected 48 SNVs in the inoculum that passed our quality and frequency cut-off filters including 21 nonsynonymous SNVs ([Table 1](#vey034-T1){ref-type="table"}). We detected only a single position (nt 7,669, EBOV glycoprotein precursor codon 544: T544I) with a nonsynonymous SNV having an allele frequency of \>10 per cent in the inoculum ([Table 2](#vey034-T2){ref-type="table"}, [Fig. 6A](#vey034-F6){ref-type="fig"}). At this position, the initial population of the inoculum consisted of alleles Thr (62.0%) and Ile (37.9%), similar to the previously characterized EBOV/Kik-9510621 'R4414' (passage 2) strain ([@vey034-B26]), and is thought to be an artifact of the previous expansions on Vero cells ([@vey034-B44]). Table 1.Passage of EBOV in HeLa and JK cells.Host cellsPassageReplicateMean coverageTotal SNVsNon-syn SNVsCoding syn SNVsNon-syn SNVs not in inoculumNon-syn SNVs in all replicatesGenome copies by RT-ddPCRGenome copies/ml by RT-ddPCRGenome copies/ml by RT-qPCRDI read fractionVero E60 46,59948216N/AN/A2.46E+084.92E+08N/A0.000276HeLa11114,4145526500N/AN/A1.06E+10N/A  250,683113521914 3.11E+101.55E+101.14E+100.000286  3114,461102461913 3.11E+101.55E+101.14E+100.000344 2157,86070329513.84E+101.92E+106.60E+090.001306  2422737938128 1.69E+108.47E+094.26E+090.001207  3110,1868636127 2.86E+101.43E+105.39E+090.001629 3184,746873712812.43E+081.22E+088.61E+090.001437  233,734542182 1.27E+106.33E+093.49E+100.001587  390,83389411010 5.39E+092.70E+092.23E+100.001721 41109,7168035131051.97E+089.86E+071.34E+100.000351  251,8578038119 8.60E+094.30E+098.53E+090.000364  391,2478035107 9.15E+094.57E+097.36E+090.000314 5179,15912060202357.43E+093.72E+095.12E+090.000320  232,086147763751 5.59E+092.79E+095.61E+090.000368  365,81790431214 9.33E+094.66E+093.12E+090.000365 6156,325422571231.91E+099.56E+089.17E+090.000512  249,650165914361 7.14E+093.57E+097.73E+090.000549  347,3325730714 1.89E+099.43E+086.98E+090.000595JK1134,97271278401.71E+098.53E+082.59E+09N/A  270,411402142 9.31E+094.65E+092.72E+090.000210  3103,515321530 2.01E+091.01E+091.98E+090.000157 217,23739206607.08E+083.54E+087.00E+08N/A  224,005251310 1.25E+096.23E+083.88E+080.000208  324,138311331 4.72E+082.36E+083.15E+080.000209 3113,13133153215.03E+082.52E+086.97E+08N/A  219,078281631 7.68E+083.84E+088.26E+080.000289  320,975482224 1.15E+095.76E+082.98E+100.000255 4118,03858259811.39E+096.95E+086.70E+08N/A  239,866492288 2.50E+091.25E+096.78E+080.000215  366,186371936 1.63E+098.15E+086.10E+080.000225 518,4757132181203.07E+081.54E+082.28E+08N/A  214,26666331318 1.22E+096.10E+082.58E+080.000326  316,46459291016 2.46E+081.23E+082.31E+080.000307 6156,1839841242321.33E+096.66E+081.31E+09N/A  254,1476433918 9.81E+084.91E+086.21E+080.000188  360,20063311520 3.07E+091.54E+091.17E+090.000225Mean53,52169331115/8 (HeLa/JK) 1.27E+10/1.7 0E+09 (HeLa/JK)  0.00078/ 0.00023 (HeLa/JK)[^1]Table 2.EBOV inoculum population sequence variation.Nucleotide positionReference alleleSNV alleleSNV %GeneCodon changeSequencing depth170CA0.93NP 3,219172TC0.84NP 3,2171805CT1.60NPP446S51,2121958CT2.38NPP497S60,4252209TC1.20NPS58029,3314397AG1.18VP35 61,2444441CT1.42VP40 52,0694643CT0.78VP40A5530,9544691AG0.83VP40S7128,1665125TC0.52VP40I216T28,9145878TG4.25VP40 36,3496023GT1.15GP 46,3546179GT1.15GPE47D47,5836324GA2.75GPV96M49,9646325TC0.57GPV96A46,7896493CT0.74GPA152V40,2126719CA0.53GPT22749,0017669CT37.95GPT544I36,8907672AC2.36GPE545A35,5207692GA1.68GPD552N35,0847888AC1.01GPK617T35,0118549AG0.98VP30R14G30,3909690AT0.97VP30 73,5979697AC0.88VP30 68,5629698GT0.87VP30 68,9929705AT0.93VP30 63,7859824AG0.54  67,23810833GA0.57VP24R163K42,27910845TA0.95VP24L167Q47,55711498GA1.21VP24 43,04011695TC1.41LN3841,71713001AG0.59LI480V43,05313234AT0.50LS55139,46513240AT0.59LK553N36,36713497CT0.57LA639V69,95814043GA1.41LR821K47,80614412AG1.78LE944G49,79917507GT0.66LD1976Y46,24017510AC0.58LN1977H45,94518259TG0.83L 41,88118528TC1.03  28,86118530AT0.98  29,39718532GA0.97  29,74318688AG1.90  34,66318827GC0.61  39,0818833GT0.70  3,57318836AC0.63  3,33118842GC0.61  3,133[^2]

![Alleles across the EBOV genome. (A) SNVs found in the EBOV passaging inoculum. The log~10~ (allele frequency) of each SNV is plotted as a function of its position in the EBOV reference genome (genome schematic drawn to scale between A and B). All SNVs are color-coded. Yellow: non-synonymous SNVs; black: synonymous and non-coding SNVs. (B) The estimated selection coefficients across the EBOV genome for passages in HeLa cells (orange) and JK cells (green). Each point represents the most positively selected allele for each site in the EBOV genome. Selection coefficients were averaged across the three replicates. (C) The allele frequency trajectories across passages of the most strongly selected sites in HeLa (left) and JK (right) cells.](vey034f6){#vey034-F6}

We then characterized variation across passages in JK and HeLa cells. From all replicates and passages, we detected a mean of 89 (σ  =  31) SNVs for passages in HeLa cells and a mean of 51 (σ  =  19) SNVs for passages in JK cells ([Table 1](#vey034-T1){ref-type="table"}, [Fig. 7A](#vey034-F7){ref-type="fig"}). Considering only nonsynonymous variants that were not already present in the inoculum, we detected a mean of 15 (σ  =  15) SNVs and 8 (σ  =  7) SNVs for all replicates and all passages in HeLa cells and JK cells, respectively ([Table 1](#vey034-T1){ref-type="table"}, [Fig. 7B](#vey034-F7){ref-type="fig"}).

![Graphs of EBOV passages versus log~10~(allele frequency) of single nucleotide variants (SNVs). Each SNV found in each passage was plotted as its log~10~(allele frequency). (A) Frequency of all SNVs from each replicate. (B) Frequency of nonsynonymous variants from each replicate that were not found in the inoculum. (C) Nonsynonymous variants found in all three replicates, but not the inoculum, were plotted as a single point with their mean frequency. Inoculum was a single replicate, whereas all other passages were pooled triplicates, except for (C). JK cells: green; HeLa cells: orange.](vey034f7){#vey034-F7}

To determine whether a change in the distribution of allele frequencies associated with EBOV SNVs detected was a function of passage or host (boa constrictor versus human) cell, we focused on a comparison of the first and last EBOV passages. The mean allele frequency associated with nonsynonymous SNVs not found in the inoculum for EBOV grown in HeLa cells was 0.009 and 0.015 in in the first passage and passage 6, respectively. The difference between these passages was statistically significant (Kolmogorov--Smirnov \[KS\] test, *P *=* *0.00051; Holm--Bonferroni adjusted *P *\<* *0.01). However, the difference in distributions of allele frequencies associated with nonsynonymous variants not found in the inoculum for EBOV grown in JK cells was not significant (KS test, *P *=* *0.41710; Holm--Bonferroni adjusted *P *\>* *0.01).

We also compared the distribution of allele frequencies associated with nonsynonymous variants not found in the EBOV inoculum between the two host cells at the last passage. The difference between their means was relatively small (HeLa and JK means of 0.015 and 0.012, respectively), and the difference between these distributions was not statistically significant (KS test, *P *=* *0.0131; Holm--Bonferroni adjusted *P *\>* *0.0083).

To further increase the stringency of our criteria for identifying biologically relevant EBOV variants, we considered only nonsynonymous variants present in all three biological replicates for each passage from each host cell that were not present, or at a frequency below the limit of detection in the inoculum ([Table 1](#vey034-T1){ref-type="table"}, [Fig. 7C](#vey034-F7){ref-type="fig"}). We detected a mean of 3 (σ  =  2) nonsynonymous SNVs across all passages in HeLa cells and a mean of 1 (σ  =  1) nonsynonymous SNVs across all passages in JK cells. We were unable to detect any EBOV SNVs that met these criteria for the first passage in either cell type. For JK cell passages, EBOV SNVs that met these criteria were only detected in passages 3, 4, and 6. In passage 6, we did not find any statistical significance between the distributions of allele frequencies of SNVs found in the HeLa cell passage versus the JK cell passage (KS test *P *=* *0.4249 versus 0.05).

Finally, we implemented a rigorous simulation-based test for neutral evolution of EBOV that takes into account sequencing error, sampling error, and an estimated demographic model representing the passages in our experiments. We found numerous variants that deviate from neutral expectations (14,473 sites in JK and 15,028 sites in HeLa cells). However, as discussed above, nearly all of these variants had extremely small changes in allele frequency. To estimate the strength of selection operating on EBOV in each cell line, we implemented a deterministic fitness model and applied it to each site in turn. We found that the estimated selection coefficients were small ([Fig. 6B](#vey034-F6){ref-type="fig"}, and [Supplementary Table S1](#sup4){ref-type="supplementary-material"}), with only two sites in each set of passages at or above 0.10. In the passages in JK cells, nucleotide 18,016 had an estimated selection coefficient of 0.11 and nucleotide 6,861 had an estimated selection coefficient of 0.10. In the passages in HeLa cells, nucleotides 18,605 and 17,168 both had an estimated selection coefficient of 0.11. These values are on the order of what is seen for selected alleles in humans (results from artificial selection experiments tend to note selection coefficients that are much larger than our results).

Together, these data indicate that EBOV can replicate in boa constrictor cells for prolonged times/passages without requiring major genomic adaptations.

3.5 Weak positive selection operates on the EBOV genome during passaging
------------------------------------------------------------------------

To identify EBOV genomic sites undergoing positive selection in JK or HeLa cells, we first excluded sites with total read coverage that was not within two SDs of the genome-wide mean (calculated by first averaging the total reads across the three replicates for each passage and then averaging all passages). After filtering, a total of 17,924 sites and 17,970 sites, covering 95 per cent of the genome, were retained for EBOV passaged on HeLa and JK cells, respectively. Only three EBOV genomic sites changed in allele frequency by at least 10 per cent, all of which were identified in JK cell-grown virus ([Fig. 7C](#vey034-F7){ref-type="fig"}, [Supplementary Table S1](#sup4){ref-type="supplementary-material"}): nucleotide positions 5,780 (located in the VP40 5′ untranslated ), 7,669 (preGP T544I), and 18,016 (L, a synonymous mutation). In HeLa cells, all allele frequency changes were less than 7 per cent ([Supplementary Table S1](#sup4){ref-type="supplementary-material"}). Using a deterministic model of positive selection (see [Supplementary Methods](#sup3){ref-type="supplementary-material"}), we estimated that the selection coefficient at all sites in the EBOV genome (across both HeLa and JK cells) was less than 12 per cent. These data suggest that weak selection can be identified in the EBOV genome over passages (particularly in JK cells; see [Supplementary Methods](#sup3){ref-type="supplementary-material"} for statistical test results), but that very little adaptation is necessary to successfully passage EBOV in either cell type.

3.6 Passage of EBOV in boa constrictor or hela cells does not lead to major production of defective interfering genomes
-----------------------------------------------------------------------------------------------------------------------

The presence of DI particles has been noted with EBOV infection of grivet (*Chlorocebus aethiops*) kidney epithelial Vero E6 cells, but DI particles remain poorly understood with only a single paper published on EBOV DI genome characterization ([@vey034-B6]). Viral DI particles often contain genomes with long deletions or genomic re-arrangements that presumably arise through errors in replication by, for instance, template switching ([@vey034-B32]). To detect the presence of EBOV genomic sequences with deletions that would likely yield DI particles, we quantified the insertion distance between sequence pairs of EBOV genomes derived from infections of both JK and HeLa cells across all passages and replicates. Distances larger than the library mean + 3σ were counted as being consistent with internal genomic deletions. The EBOV inoculum featured 0.0276 per cent of reads that were consistent with internal genomic deletions. We detected a low level of reads consistent with internal genomic deletion sequences in all passages and replicates on both cell types (mean = 0.0780 per cent (σ  =  0.0535) of reads and 0.0234 per cent (σ  =  0.00480) of reads for passages on HeLa cells and JK cells, respectively) distributed across the EBOV genome ([Table 1](#vey034-T1){ref-type="table"}, [Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). By the final passage, this value changed to 0.0552 per cent (σ  =  0.00340) and 0.0206 per cent (σ  =  0.00185) of reads for the passage on HeLa and JK cells, respectively. In this analysis, we cannot rule out the possibility of internal deletions produced during sequencing library preparation, and thus these measurements are likely to be overestimates. Regardless, this analysis indicates that sequences consistent with the presence of DI particles could be detected, but only at very low frequencies.

3.7 EBOV does not cause cytopathic effects in snake cells
---------------------------------------------------------

EBOV GP~1~,~2~ is thought to be the major cause of the CPE typically seen in EBOV cell culture models ([@vey034-B65]). Typically, GP~1~,~2~ overexpression results in cell rounding, cell detachment, and cell death. Similar to the method used by [@vey034-B65] to estimate cytopathic effects of EBOV infection, EBOV-exposed JK cells were stained with Hoechst 33342, imaged, and counted. When compared to mock infection, viable EBOV-infected JK cells did not decrease in number dramatically unlike that observed in many other cell lines ([@vey034-B16]). At 72 h post-inoculation, we counted a mean of 3,387 (σ  =  65) cells/well for wells of mock-infected JK cells and 1,637 (σ  =  51) cells/well for wells of mock-infected DpHt cells, whereas EBOV-exposed JK cells were counted at 3,276 (σ  =  679) cells/well, 3,471 (σ  =  71) cells/well, and 3,353 (σ  =  67) cells/well as the MOI increased to 1, 5, or 10, respectively ([Fig. 3B](#vey034-F3){ref-type="fig"}). While EBOV-exposed cells at MOIs of 1 and 5 represent statistically significant changes from mock-infected (Welch's *t*-test *P *=* *0.001 and *P *=* *0.018, respectively), exposure at MOI of 10, which infected a mean of 99 per cent of the cells, showed no significant difference (*P *=* *0.294). As the MOI increased to 1, 5, or 10 in EBOV-exposed DpHt cells, cells were counted at 1,458 (σ  =  67) cells/well, 1,459 (σ  =  90) cells/well, or 1,492 (σ  =  72) cells/well, respectively. These values represent statistically significant changes from mock-infected (Welch's *t*-test *P *=* *0.00001, *P *=* *0.0002, *P *=* *0.0002 as the MOI increased to 1, 5, or 10, respectively), but the values are not dose-dependent. Additionally, based on cytoplasmic and nuclear staining of EBOV-infected JK cells, we did not note any obvious morphological changes ([Fig. 4](#vey034-F4){ref-type="fig"}).

4. Discussion
=============

The natural reservoir of EBOV and all other ebolaviruses pathogenic for humans remains unclear. Marburgviruses (both MARV and RAVV) were isolated from wild Ugandan Egyptian rousettes (*Rousettus aegyptiacus*) and also were used to infect these bats experimentally ([@vey034-B55]; [@vey034-B1]; [@vey034-B22]). Such findings have not been reported for pathogenic ebolaviruses, thereby raising the possibility that marburgviruses and ebolaviruses may differ in host tropism (e.g., bats of different taxa) and may even infect animals of different orders ([@vey034-B57]; [@vey034-B22]; Jensen [@vey034-B21]; [@vey034-B33]; [@vey034-B40]). Experimental filovirus inoculations into taxonomically diverse animals to determine host tropism have only rarely been reported. These experiments suggest that all isolated filoviruses can infect and are frequently lethal for various nonhuman primates (common marmosets \[*Callithrix jacchus*\], common squirrel monkeys \[*Saimiri sciureus*\], crab-eating macaques \[*Macaca fascicularis*\], grivets \[*Chlorocebus aethiops*\], hamadryas baboons \[*Papio hamadryas*\], and rhesus monkeys \[*Macaca mulatta*\]). Most filoviruses can be adapted in the laboratory to infect and kill various rodents (golden hamsters \[*Mesocricetus auratus*\], guinea pigs \[*Cavia porcellus*\], laboratory mice), and some filoviruses can infect domestic pigs (*Sus scrofa*). Various plants, goats (*Capra hircus*), horses (*Equus caballus*), and red sheep (*Ovis aries*) were found to be resistant to experimental filovirus infection (summarized in ([@vey034-B53]; [@vey034-B29]; [@vey034-B5])). Interestingly, domestic ferrets (*Mustela putorius furo*) develop disease after experimental infection with various ebolaviruses([@vey034-B9]; [@vey034-B24]; [@vey034-B25]), whereas MARV or RAVV exposure does not lead to productive infection ([@vey034-B10]; [@vey034-B62]).

In 2001, a possible genetic link between mammalian arenaviruses (family *Arenaviridae*, genus *Mammarenavirus*) and the mononegaviral filoviruses was suggested based on similarities between mammarenaviral GP2 and filoviral GP~2~ ([@vey034-B11]). This possible link was further substantiated by the structural characterization of GP2 from a newly discovered snake reptarenavirus, CAS virus (genus *Reptarenavirus*), which revealed striking structural similarities to filovirus GP~2~ ([@vey034-B23]). Reptarenaviruses are known to infect captive snakes (boas and pythons) ([@vey034-B50]; [@vey034-B3]; [@vey034-B17]; [@vey034-B52]), whereas filoviruses infections have not been associated with reptiles. In fact, the thus-far tested reptilian cell lines (e.g., iguana IgH-2, rattlesnake 8625, common box turtle Th-1, Russell's viper VH 2, VSW cells) proved resistant to EBOV infection ([@vey034-B56]; [@vey034-B37]). Filoviral GP~1~,~2~s engage endosomal mammalian Niemann-Pick disease, type C1 protein (NPC1) to gain entry into host cells ([@vey034-B8]; [@vey034-B57]). Previously published cell-culture experiments have shown that a single amino acid (Y503), when changed to the analogous human residue (Y503F), causes VH-2 cells to become permissive to EBOV infection ([@vey034-B37]).

Whether boa constrictor NPC1 would allow filovirus entry into host cells was not known because although the boa constrictor genome has been assembled, it has not been annotated ([@vey034-B4]). We used a comparative alignment approach and mapping of transcriptome-derived short sequence reads to predict the boa constrictor NPC1 protein sequence (Genbank [KY595070](KY595070)). The predicted sequence has a Phe residue at the critical position (F517, homologous to F503 in human NPC1), which suggested that boa constrictor cells could be permissive to EBOV infection. Snakes of some species may have been subject to selection by viruses with filovirus-like glycoproteins ([@vey034-B37]).

To experimentally test whether snake cells actually support filovirus replication, we exposed boa constrictor JK cells and diamond python DpHt cells to EBOV and MARV. While MARV infection was not productive in these cells, both JK and DpHt cells supported EBOV infection. EBOV infection of JK cells occurred in the absence of CPE, an observation that has been reported only rarely ([@vey034-B56]). In addition, JK cells supported EBOV replication over six passages in the absence of major genomic adaptation. Only one genomic position, 7,669, (EBOV preGP T544I) switched major alleles (38%--52%). After maturation of the glycoprotein precursor (preGP), this residue resides in the preGP cleavage product GP~2~. The residue is a critical structural determinant of the EBOV GP~2~ fusion loop, which mediates fusion of the filovirion membrane with the host-cell membrane to initiate virion entry ([@vey034-B14]) but could represent a previously identified filovirus cell-culturing artifact ([@vey034-B44]).

Both alleles, Thr and Ile, are found in different EBOV isolate sequences. For instance, unpassaged isolates of the EBOV Makona variant ([@vey034-B28]b), which caused the 2013--2016 Western African EVD outbreak, almost exclusively encode Thr at pre-GP position 544 ([@vey034-B2]; [@vey034-B12]; [@vey034-B7]; [@vey034-B31]; [@vey034-B39]; [@vey034-B48]; [@vey034-B54]), whereas the passaged 1976 EBOV Yambuku variant isolate encodes the Ile allele ([@vey034-B27]). Likewise, Ile is also encoded at the homologous position in the genome of passaged RESTV ([@vey034-B20]; [@vey034-B15]), which has not yet been associated with human infections. We detected weak positive selection favoring the Ile allele in the EBOV passages in JK cells, suggesting this allele provides a fitness advantage over Thr for infection in JK cells. However, the mechanistic reason for this selection remains to be determined.

In contrast to the successful infections of both rVSV-EBOV and rVSV-MARV, JK cells only supported infection with EBOV. JK cells were unable to support productive MARV infection as demonstrated by the qPCR on viral passaging samples. Taken together, EBOV and MARV are markedly different in their abilities to infect snake cells. Our results suggest that the lack of productive MARV infection in snake cells may be due to a block in the viral lifecycle downstream of virion internalization. Uncovering the molecular underpinnings of this apparent filovirus genus-specific (*Ebolavirus* versus *Marburgvirus*) difference could increase our understanding of filovirus tropism.

Importantly, we do not suggest here that snakes are natural host reservoirs of ebolaviruses (although we also do not rule out this possibility). The cells examined in this study originate from snakes that occur exclusively in South America (boa constrictors) or Australia (diamond pythons)---geographic areas in which filoviruses have not been found thus far. Cell lines from snakes living in Africa or *in vivo* infections of African snakes with filoviruses would have to be performed to even establish a host reservoir hypothesis. Furthermore, filovirus cell tropism *in vitro* does not necessarily predict *in vivo* tropism. For instance, Egyptian rousette cell lines are readily infectable with both marburgviruses and ebolaviruses, but Egyptian rousettes can only be naturally and experimentally infected with marburgviruses and not with ebolaviruses. Our positive EBOV infection results in boa constrictor JK cells, therefore, does not automatically support the idea that boa constrictors could be infected with EBOV. Together, however, our observations raise the possibility that ebolaviruses and marburgviruses could infect evolutionary disparate hosts, possibly even of different animal orders (e.g., mammals versus other classes). Our results suggest that additional nonmammalian cell lines should be screened for filovirus permissiveness to widen or narrow the search for natural filovirus hosts, followed by experimental animal exposures for validation of in vitro results.
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[^1]: syn, synonymous; DI, defective interfering.

[^2]: Shown is each of the SNVs found above the cut-off in the inoculum population.
